With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL1131
Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status
Patients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol therapy (other than allowed in above criteria) are excluded
Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible
ALL developing after a previous cancer treated with cytotoxic chemotherapy
Patients who have received any prior cytotoxic chemotherapy or biologics for sex cord-stromal tumors (SCSTs)
Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to biopsy
Patients with AML must be unlikely to benefit from cytotoxic chemotherapy defined by any one of the following criteria:
At the time of registration: patients must have recovered from the toxic effects of prior therapy: >= 28 days from any investigational agent, >= 28 days from prior cytotoxic therapy, >= 14 days from vincristine, >= 42 days from nitrosoureas, >= 21 days from procarbazine administration, and >= 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the principal investigator
Must not have received cytotoxic chemotherapy within 14 days of entry on to this study
Cytotoxic chemotherapy -2 weeks
Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol
Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded
Cytotoxic chemotherapy or immunotherapy within 3 weeks of study entry
Prior cytotoxic chemotherapy is allowed.
Any cytotoxic chemotherapy within 21 days prior to initiation of study drug.
Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment
Treatment with cytotoxic or targeted antineoplastics within 3 weeks of initiation of study treatment. For cytotoxic agents that have major delayed toxicity a washout period of one cycle is indicated (examples are nitrosoureas and mitomycin C which typically require a 6 week washout). Prior antibodies or immunotherapies require a 6 week washout.
>= 2 weeks off cytotoxic chemotherapy
Received any other investigational agent or systemic cytotoxic chemotherapy within the preceding 2 weeks
Chemotherapy: at least 2 weeks since prior cytotoxic chemotherapy
Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol
Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded
In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents.
Prior cytotoxic chemotherapy or biologic therapy for prostate cancer
Any cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drug
Treatment with cytotoxic chemotherapy within 3 months prior to enrollment
Previous or concurrent cytotoxic chemotherapy for prostate cancer
Patients may have received one additional non-cytotoxic regimen for management of recurrent or persistent disease according to the following definition: non-cytotoxic (biologic or cytostatic) agents include (but are not limited to) hormones, monoclonal antibodies, cytokines, and small molecule inhibitors of signal transduction
Has received cytotoxic chemotherapy for post-transplant relapse prior to study entry
Any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within 2 weeks of enrollment
Prior therapy requirements:\r\n* Wt-GIST: previously untreated participants are eligible\r\n* PHEO/PGL with germline SDH subunit mutation: 131I-methyl-iodobenzylguanine (MIBG) in patients with MIBG avid tumors or cytotoxic chemotherapy (cyclophosphamide, vincristine, and dacarbazine [CVD] or temozolomide) is required prior to enrollment on this trial; however, patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible\r\n* HLRCC-associated renal cell cancer: previously untreated participants are eligible
Subjects receiving cytotoxic chemotherapy
No previous cancer treatment with any cytotoxic agent for this malignancy
Be at least 28 days from last administration of cytotoxic chemotherapy or other investigational agent
Prior cytotoxic chemotherapy or radiotherapy for this lymphoma
Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy
PHASE 2 ONLY: Patient participants previously untreated for AML who are considered unfit for cytotoxic chemotherapy by virtue of performance status, comorbidities, advanced age and/or low likelihood of response based on disease characteristics, or who decline cytotoxic induction chemotherapy
Patients must have been previously treated, as defined by treatment with at least one prior cytotoxic chemotherapy regimen or agent; patients may have received any number of prior cytotoxic agents
Prior systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible
Patients must be >= 14 days from previous cytotoxic treatment
Cytotoxic chemotherapy within 21 days prior to enrollment
Chemotherapy: cytotoxic (At least 21 days since last dose of chemotherapy prior to first dose of tazemetostat)
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least 14 days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
At the time of registration, patient must be at least 4 weeks from other prior cytotoxic chemotherapy
May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.
No intention to use cytotoxic chemotherapy within the next 6 months
Treatment with cytotoxic chemotherapy within previous 28 days, or failure to recover from adverse events (AEs) due to cytotoxic chemotherapy administered more than 28 days previous (however, ongoing neuropathy is permitted)
Previous or concurrent cytotoxic chemotherapy for prostate cancer
At the time of treatment on protocol patients must have recovered from the toxic effects of prior therapy: > 10 days from any noncytotoxic investigational agent, > 28 days from prior cytotoxic therapy or Avastin, > 14 days from vincristine, > 42 days from nitrosoureas, > 21 days from procarbazine administration, and > 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the study chair
Ongoing treatment with cytotoxic therapy
Patients with active cytotoxic chemotherapy or radiation therapy are excluded
Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks before the first dose of study treatment
Cohort A: patients who have received prior cytotoxic chemotherapy, such as anthracyclines and cytarabine not permitted; but prior treatment with demethylating agents (azacytidine or decitabine), lenalidomide etc ALLOWED
Patients must have recovered from the toxic effects of prior therapy and be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy; any questions related to the definition of non-cytotoxic agents should be directed to the principal investigators; for those who have received radiation, 4 weeks must have elapsed before beginning vaccination
Patients must have recovered from the toxic effects of prior therapy: > 3 weeks for biologic therapies or non-cytotoxic therapies, > 4 weeks for cytotoxic therapies, and > 6 weeks for nitrosoureas; any questions related to the definition of non-cytotoxic agents should be directed to the study chair\r\n* NOTE: 13 cis-retinoic acid (Accutane) as biologic therapy has a washout period of 14 days
Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC; Note: sipulecel-T is permitted with a 2-week washout
Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy (prior taxane chemotherapy allowed).
Must not have received cytotoxic chemotherapy within 14 days of entry on to this study
Patients on Strata C and D must have recovered from the toxic effects of prior therapy to grade 1 or better; patients must be at least 3 weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy, at least 1 week from the last dose of non-myelosuppressive biologic therapy and at least 6 months from placement of bis-chloroethylnitrosourea (BCNU) wafers; any questions related to the definition of non-cytotoxic agents should be directed to the principal investigator
Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen
Prior treatment with cytotoxic chemotherapy for advanced NSCLC
1 week from non-cytotoxic agents
Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.
Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving cisplatin, 5-FU or pemetrexed)
Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered)
Previous cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor. Subjects who received Gliadel wafers will be excluded.
Nitrosourea cytotoxic drug ? 6 weeks
Not eligible for cytotoxic therapies
Any cytotoxic or biologic therapy less than 2 weeks prior to initiation of therapy.
Patients treated with prior chemotherapy, cytotoxic chemotherapy, radiation, biotherapy, or any investigational agent > 30 days prior to lymph node removal are eligible
4 weeks from prior cytotoxic therapy
Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea, low dose cytarabine, and intrathecal chemotherapy which is permitted up to 24 hours prior to the start of protocol therapy; for patients with aggressive disease that is in the peripheral blood and rising, this 14 day washout period may be omitted
At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy
Prior cytotoxic chemotherapy or radiotherapy for this lymphoma
Chemotherapy: cytotoxic (At least 21 days since last dose of chemotherapy prior to first dose of tazemetostat)
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least 14 days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of 6 months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum 4 weeks has elapsed since their last infusion of biological therapy
Cytotoxic chemotherapy within 14 days before randomization
Cancer for which intraperitoneal cytotoxic chemotherapy is planned
Eligible for cytotoxic chemotherapy
Chemotherapy: cytotoxic At least 21 days
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) At least 14 days
Prior cytotoxic chemotherapy;
No prior cytotoxic chemotherapy to treat their metastatic disease
Cytotoxic chemotherapy within 3 weeks of first trilaciclib (G1T28) dose
Cytotoxic chemotherapy; at least 21 days since last dose
Non-cytotoxic chemotherapy (e.g., small molecule inhibitor); at least 14 days since last dose
Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within 3 weeks of study treatment for OCCC
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 3 weeks of the first dose of study medication
Any cytotoxic chemotherapy,or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen within 14 days of the first dose of study treatment
Investigation or cytotoxic therapy within 28 days or nitrosoureas within 42 days of the first treatment with G-202
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 21 days of the first dose of trial medication
Less than 7 days from the completion of any previous cytotoxic chemotherapy (with the exception of hydroxyurea)
Cytotoxic chemotherapy within the 28 days prior to randomization
Following prior treatments are not eligible:\r\n* Use of any investigational agent within 30 days preceding enrollment\r\n* Treatment with cytotoxic chemotherapy within previous 4 weeks\r\n* Failure to achieve =< grade 2 adverse events (AE) resolution from cytotoxic chemotherapy administered more than 4 weeks previous (however, ongoing neuropathy is permitted)\r\n* Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or Ra-223 dichloride) for the treatment of bony metastases
Patients who have received prior cytotoxic chemotherapy for castration-resistant prostate cancer unless enrolled in a previous chemotherapy cohort.
Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.
No cytotoxic chemotherapy within 2 weeks of starting study treatment
Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes, mitoxantrone and estramustine
Treatment with cytotoxic chemotherapy for prostate cancer within the previous 4 weeks prior to randomization, or planned treatment with cytotoxic chemotherapy agents for prostate cancer during the treatment period or follow-up
Subject with rapidly progressing visceral disease who has not received and is thought to be able to tolerate cytotoxic chemotherapy. (However, subject who has previously received cytotoxic chemotherapy is permitted).
Prior cytotoxic chemotherapy or biologic therapy for the treatment of castration-resistant prostate cancer (CRPC)
Prior cytotoxic chemotherapy or biologic therapy for the treatment of castrate-resistant prostate cancer (CRPC)
At the time of registration; patients must have recovered from the toxic effects of prior therapy:\r\n* >= 28 days from any investigational agent\r\n* >= 28 days from prior cytotoxic therapy\r\n* >= 14 days from vincristine\r\n* >= 42 days from nitrosoureas\r\n* >= 21 days from procarbazine administration\r\n* > 21 days from bevacizumab administration and\r\n* >= 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the Academic principal investigator (PI)
Patients must be at least 21 days post cytotoxic chemotherapy prior to enrollment
At least 21 days from the completion of any previous cytotoxic chemotherapy or biological therapy at time of initiation of POL6326.
Having recovered from prior surgery, radiation, chemotherapy (cytotoxic and noncytotoxic) to toxicity grade =< 1 or returned to baseline; previous treatment with immunotherapies, cytotoxic drugs, or other targeted agents is permitted; if cytotoxic chemotherapy was previously received, the last dose must be >= 1 month before leukapheresis; for other agents, the last dose must be >= 14 days before leukapheresis
Prior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is allowable and if used as a single agent should not be considered as a cytotoxic chemotherapy (nor should other targeted therapies be considered as a prior line of cytotoxic chemotherapy)
Previous cytotoxic chemotherapy for advanced (metastatic) disease
Prior cytotoxic chemotherapy or biologic therapy for prostate cancer
Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 2 weeks of study
Prior bevacizumab and any cytotoxic chemotherapy
More than 2 prior lines of cytotoxic chemotherapy
Cytotoxic chemotherapy: ? duration of the most recent cycle of the previous regimen (a minimum of 2 weeks for all)
Patients must have recovered from the toxic effects of prior therapy including but not limited to: \r\n* An interval of >= 4 weeks (28 days) from prior cytotoxic therapy except 6 weeks from nitrosoureas\r\n* An interval of >= 1 week (7 days) from any non-cytotoxic agents\r\n* An interval of >= 3 months from the completion of radiation therapy
No prior treatment with cytotoxic chemotherapy
No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.
Previous cytotoxic chemotherapy (e.g. alkylating chemotherapy, anthracyclines, and vinca alkaloids), radiation therapy, and any experimental therapy within the context of a clinical trial must have been discontinued at least 28 days prior to entry onto this study
Systemic cytotoxic therapy within 3 weeks of treatment
Prior cytotoxic or cyclosporin treatment for HLH.
Patients with prior cytotoxic chemotherapy are eligible to participate if they have been progression free for at least 12 months since the initiation of cytotoxic chemotherapy
Candidates for cytotoxic chemotherapy
14 days for non-cytotoxic cancer therapies and radiotherapy
Previous or concurrent cytotoxic chemotherapy for prostate cancer
A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen.
Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within 3 months of enrollment
4 weeks from prior cytotoxic therapy
Any prior cytotoxic chemotherapy except Temozolomide
Patients must have had prior cytotoxic therapy for their disease; patients with diffuse large B-cell lymphoma must have been treated with at least 2 prior cytotoxic therapies
Patients must have received at least 1 line of cytotoxic chemotherapy
Patients may have had up to two prior cytotoxic chemotherapy regimens for their disease (immunological or targeted therapy e.g. vaccine, IL-2, B-RAF inhibitors, will not be considered prior cytotoxic chemotherapy). Patient should not have been treated with Docetaxel, Paclitaxel or other taxanes.
More than 1 prior cytotoxic chemotherapy regimen for advanced disease
Patient has had prior cytotoxic chemotherapy for the treatment of metastatic melanoma; however, patients who are randomized to the physician’s choice arm and treated with cytotoxic chemotherapy as part of this study will be allowed to cross over to receive their assigned molecularly guided therapy should disease progression occur and they meet the specific eligibility requirements of the molecularly guided agent
Positive cytotoxic crossmatch
Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within 3 months of enrollment
Patient has received more than one line of cytotoxic chemotherapy
Concurrent anti-cancer cytotoxic chemotherapy
Use of cytotoxic chemotherapy within 21 days of registration
Prior cytotoxic chemotherapy for metastatic prostate cancer
Prior cytotoxic chemotherapy or biologic therapy for CRPC
Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment with one line of cytotoxic chemotherapy is permitted; prior treatment with targeted therapy (such as ipilimumab, anti-programmed cell death 1 [PD1] and BRAF inhibitor) is permitted
At least 21 days from last cytotoxic chemotherapy
Scheduled to start a new chemotherapy regimen (any line, combination cytotoxic chemotherapy with targeted agents are allowed)
Treatment with cytotoxic chemotherapy within 4 weeks prior to registration
Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 7 days of study entry
Received cytotoxic chemotherapy within 21 days (or 42 days for nitrosureas or mitomycin C) prior to the first scheduled dose of MEDI7247.
Cytotoxic chemotherapy within 4 weeks.
28 days from administration of prior cytotoxic therapy with the following exceptions:
About to begin either oral or cytotoxic chemotherapy
1 month – 5 years following completion of cytotoxic chemotherapy treatment for any cancer, and are experiencing neuropathy
Planned cytotoxic chemotherapy during the WBRT only; patients may have had prior chemotherapy
Treatment with cytotoxic chemotherapy within the preceding four weeks
Patients who have not had any cytotoxic chemotherapy within 14 days of beginning the study
Currently on or expected to start cytotoxic chemotherapy within 1 week of study enrollment
Participants who have received cytotoxic chemotherapy within 1 year prior to screening breast MRI
Subjects must have received cytotoxic chemotherapy within 3 months of consent date (measured from the start date of chemotherapy).
Cytotoxic chemotherapy within 4 weeks prior to study enrollment
Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within defined values prior to start of study treatment
